Addex Therapeutics Ltd (ADXN)
11.01
+0.31
(+2.90%)
USD |
NASDAQ |
Nov 04, 13:35
Addex Therapeutics Enterprise Value: 7.218M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 7.218M |
| October 31, 2024 | 6.203M |
| October 30, 2024 | 7.240M |
| October 29, 2024 | 6.908M |
| October 28, 2024 | 7.550M |
| October 25, 2024 | 7.550M |
| October 24, 2024 | 8.137M |
| October 23, 2024 | 7.389M |
| October 22, 2024 | 7.186M |
| October 21, 2024 | 6.791M |
| October 18, 2024 | 6.940M |
| October 17, 2024 | 7.112M |
| October 16, 2024 | 7.058M |
| October 15, 2024 | 6.951M |
| October 14, 2024 | 7.005M |
| October 11, 2024 | 6.748M |
| October 10, 2024 | 6.834M |
| October 09, 2024 | 6.727M |
| October 08, 2024 | 6.834M |
| October 07, 2024 | 5.76M |
| October 04, 2024 | 5.872M |
| October 03, 2024 | 5.829M |
| October 02, 2024 | 5.701M |
| October 01, 2024 | 5.647M |
| September 30, 2024 | 6.224M |
| Date | Value |
|---|---|
| September 27, 2024 | 5.455M |
| September 26, 2024 | 6.075M |
| September 25, 2024 | 6.417M |
| September 24, 2024 | 6.695M |
| September 23, 2024 | 7.112M |
| September 20, 2024 | 6.299M |
| September 19, 2024 | 6.118M |
| September 18, 2024 | 6.032M |
| September 17, 2024 | 6.609M |
| September 16, 2024 | 6.577M |
| September 13, 2024 | 6.086M |
| September 12, 2024 | 6.695M |
| September 11, 2024 | 6.791M |
| September 10, 2024 | 7.049M |
| September 09, 2024 | 7.518M |
| September 06, 2024 | 7.731M |
| September 05, 2024 | 7.870M |
| September 04, 2024 | 7.218M |
| September 03, 2024 | 8.052M |
| August 30, 2024 | 7.389M |
| August 29, 2024 | 6.716M |
| August 28, 2024 | 7.122M |
| August 27, 2024 | 8.159M |
| August 26, 2024 | 3.970M |
| August 23, 2024 | 3.959M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-9.505M
Minimum
Jun 28 2022
87.48M
Maximum
Dec 24 2020
14.25M
Average
7.813M
Median
May 08 2024
Enterprise Value Benchmarks
| AC Immune SA | 102.01M |
| CRISPR Therapeutics AG | 3.839B |
| NLS Pharmaceutics Ltd | 14.90M |
| Molecular Partners AG | 26.06M |
| MoonLake Immunotherapeutics | 2.430B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 14.24M |
| Revenue (Quarterly) | 0.1275M |
| Total Expenses (Quarterly) | 1.122M |
| EPS Diluted (Quarterly) | 10.62 |
| Earnings Yield | -14.92% |
| Normalized Earnings Yield | -96.68 |